Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 468 - 468
Published: Jan. 30, 2025
Acral melanoma (AM), also known as acral lentiginous (ALM), is a rare subtype of that predominantly occurs on the palms, soles, and nail beds (Figure 1) [...]
Language: Английский
Citations
1Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects
Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 201, P. 104426 - 104426
Published: June 20, 2024
Immunotherapy has transformed the treatment of advanced melanoma. However, up to two-thirds patients experience disease progression after initially achieving a response immunotherapy. Furthermore, most research focused on cutaneous melanoma rather than acral or mucosal melanoma, although latter predominates in Asian populations. In this review, we examine and summarize current definitions resistance immunotherapy epidemiology PD-1 inhibition. We also review available literature molecular mechanisms resistance, including how tumor mutational landscape microenvironments immunotherapy-resistant melanomas may influence resistance. Finally, strategies for overcoming inhibition completed studies ongoing clinical trials. Our highlights that improving understanding mechanisms, optimizing existing therapies further studying high-risk populations would maximize potential result optimized outcomes with
Language: Английский
Citations
4Acral Melanoma: A Review of Its Pathogenesis, Progression, and Management
Biomolecules, Journal Year: 2025, Volume and Issue: 15(1), P. 120 - 120
Published: Jan. 14, 2025
Acral melanoma is a distinct subtype of cutaneous malignant that uniquely occurs on ultraviolet (UV)-shielded, glabrous skin the palms, soles, and nail beds. While acral only accounts for 2–3% all melanomas, it represents most common among darker-skinned, non-Caucasian individuals. Unlike other does not arise from UV radiation exposure accordingly associated with relatively low tumor mutational burden. Recent advances in genomic, transcriptomic, epigenomic sequencing have revealed genetic alterations unique to melanoma, including novel driver genes, high copy number variations, complex chromosomal rearrangements. This review synthesizes current knowledge clinical features, epidemiology, treatment approaches focus pathogenesis gives rise its landscape. These findings highlight need deepen our molecular understanding better target this challenging melanoma.
Language: Английский
Citations
0Managing Telomerase and Telomere Dysfunction in Acral Melanoma
Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107700 - 107700
Published: March 1, 2025
Acral Lentiginous Melanoma is a rare and aggressive subtype of melanoma that commonly affects the palms, soles, nail beds. It more prevalent in individuals with darker skin tones, including Asian, African, Hispanic populations. Unlike cutaneous melanomas, acral not associated UV exposure has distinct genetic molecular profile, underscoring need for tailored research treatment strategies. Standard treatments, such as surgery, chemotherapy, immunotherapy, targeted therapies, have shown limited success this subtype, highlighting urgency developing effective interventions. Telomerase an enzyme extends telomeres key target which exhibits' high telomerase activity, driven by mutations reverse transcriptase TERT promoter, contributes to uncontrolled tumor cell proliferation, cancer immortality, resistance conventional therapies. Therefore, targeting presents promising therapeutic avenue patients who do respond well current treatments. Several approaches deregulation been developed, their potential management discussed review. Specifically, promise telomerase-targeted therapies emphasized explores how these strategies could improve outcomes challenging cancer. By focusing on role tumorigenesis resistance, hold foundational component melanoma, complementing existing approaches.
Language: Английский
Citations
0The Rarity in the Rarity: A Rare Case of Bednar Tumor (Pigmented Dermatofibrosarcoma Protuberans) Localized on Acral Skin With Negative COL1A1-PDGFB Fusion on Fluorescence In Situ Hybridization
American Journal of Dermatopathology, Journal Year: 2025, Volume and Issue: unknown
Published: April 2, 2025
Dermatofibrosarcoma protuberans (DFSP) is a rare, low-grade fibroblastic tumor that typically exhibits CD34 positivity and storiform growth pattern. Although commonly found on the trunk proximal extremities, DFSP can also present in less frequent locations, such as head, neck, acral sites. This report discusses rare case of pigmented DFSP, known Bednar tumor, located back left hand 48-year-old woman. Histological examination revealed mesenchymal proliferation with pattern occasional dendritic melanocytes. Immunohistochemical analysis confirmed strong while excluding other markers. Despite absence typical COL1A1-PDGFB gene fusion, diagnosis was rendered. underscores importance considering differential diagnoses tumors suggests possibility noncanonical genetic rearrangements occurring atypical locations. The patient remains under close clinical ultrasound follow-up because potential for local recurrence.
Language: Английский
Citations
0Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy
Molecules, Journal Year: 2024, Volume and Issue: 29(22), P. 5239 - 5239
Published: Nov. 6, 2024
Melanoma occurs in various forms and body areas, not only the cutis, but also mucous membranes uvea. Rarer subtypes of that cancer differ genomic aberrations, which cause their minor sensibility to regular cutaneous melanoma therapies. Therefore, it is essential discover new strategies for treating rare melanoma. In recent years, interest applying CDK inhibitors (CDKIs) therapy has grown, as they are able arrest cell cycle inhibit proliferation. Current studies highlight selective CDK4/6 inhibitors, like palbociclib or abemaciclib, a very promising therapeutic option, since were accepted by FDA advanced breast treatment. However, cells every subtype do react CDKIs same way, partly because genetic differences between them. Herein, we discuss past current research relevant targeting CDKs mucosal, uveal acral melanomas. We briefly describe issue amelanotic desmoplastic types need more dysregulations, growth mentioned cancer.
Language: Английский
Citations
2Most Common Drug Eruptions by Pattern and Drug Class: A Review
Published: March 8, 2024
Cutaneous drug reactions come in many different morphologies, distributions and severities ranging from pruritus erythema to diffuse epidermal denudation requiring hospitalization. The wide variety of presentations medications responsible make identification elimination the offending agent difficult. Here these authors present a review common morphologic eruptions their drugs.
Language: Английский
Citations
1Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: July 30, 2024
Mucosal melanoma (MM) poses a significant clinical challenge due to its aggressive nature and limited treatment options. In recent years, immunotherapy has emerged as promising strategy for MM, with particular focus on immune checkpoint inhibitors such PD-1 CTLA-4 inhibitors. These have demonstrated substantial efficacy by harnessing the body’s response against tumors. Moreover, adoptive cell transfer (ACT), anti-angiogenic therapy, combination therapies garnered attention their potential in MM treatment. ACT involves modifying T cells target cells, showing antitumor activity. Anti-angiogenic therapy aims impede tumor growth inhibiting angiogenesis, while therapies, including targeted offer multifaceted approach overcome resistance. This comprehensive review explores advancements highlighting role of diverse therapeutic modalities enhancing outcomes addressing challenges posed this malignancy.
Language: Английский
Citations
1Strongly ROS-Correlated, Time-Dependent, and Selective Antiproliferative Effects of Synthesized Nano Vesicles on BRAF Mutant Melanoma Cells and Their Hyaluronic Acid-Based Hydrogel Formulation
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(18), P. 10071 - 10071
Published: Sept. 19, 2024
Cutaneous metastatic melanoma (CMM) is the most aggressive form of skin cancer with a poor prognosis. Drug-induced secondary tumorigenesis and emergency drug resistance worsen an already worrying scenario, thus rendering urgent development new treatments not dealing mutable cellular processes. Triphenyl phosphonium salts (TPPSs), in addiction to acting as cytoplasmic membrane disruptors, are reported be mitochondria-targeting compounds, exerting anticancer effects mainly by damaging their membranes causing depolarization, impairing mitochondria functions DNA, triggering oxidative stress (OS), priming primarily apoptotic cell death. TPP-based bola amphiphiles capable self-forming nanoparticles (NPs) enhanced biological properties, commonly observed for nanomaterials. Already employed several other biomedical applications, per se selective potent antibacterial TPP amphiphile have only recently been demonstrated on 50 multidrug resistant (MDR) clinical superbugs, well its exceptional properties sensitive MDR neuroblastoma cells. Here, aiming at finding molecules possibly developable counteracting CMM, this (BPPB) investigated against two BRAF mutants CMM lines (MeOV MeTRAV) excellent results (even IC50 = 49 nM MeOV after 72 h treatment). With these findings considering low cytotoxicity BPPB different mammalian non-tumoral red blood cells (RBCs, selectivity indexes up 299 treatment), possible future topical treatment lesions was presumed. aim, biodegradable hyaluronic acid (HA)-based hydrogel formulation (HA-BPPB-HG) prepared without using any potentially toxic crosslinking agents simply dispersing suitable amounts ingredients water sonicating under gentle heating. HA-BPPB-HA completely characterized, promising outcomes such high swelling capability, porosity, viscous elastic rheological behavior.
Language: Английский
Citations
0Adjuvant Therapy in Acral Melanoma: A Systematic Review
Clinical Cosmetic and Investigational Dermatology, Journal Year: 2024, Volume and Issue: Volume 17, P. 2141 - 2150
Published: Sept. 1, 2024
Acral melanoma presents distinct biological characteristics compared to cutaneous melanoma. While adjuvant therapeutic strategies for high-risk resected acral closely resemble those melanoma, the evidence supporting clinical application of therapy remains inadequate. Our aim was systematically analyze efficacy and safety profile in
Language: Английский
Citations
0